Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
2005934 citationsSandrine Faivre, Catherine Delbaldo et al.Journal of Clinical Oncologyprofile →
A phase II study
2000609 citationsMichel Ducreux, M Forni et al.European Journal of Cancerprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Jean‐Pierre Armand
Since
Specialization
Citations
This map shows the geographic impact of Jean‐Pierre Armand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Pierre Armand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Pierre Armand more than expected).
Fields of papers citing papers by Jean‐Pierre Armand
This network shows the impact of papers produced by Jean‐Pierre Armand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Pierre Armand. The network helps show where Jean‐Pierre Armand may publish in the future.
Co-authorship network of co-authors of Jean‐Pierre Armand
This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Pierre Armand.
A scholar is included among the top collaborators of Jean‐Pierre Armand based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Jean‐Pierre Armand. Jean‐Pierre Armand is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Massard, Christophe, Margarita Majem, Jean‐Charles Soria, et al.. (2007). Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors. Molecular Cancer Therapeutics. 6.3 indexed citations
4.
Dhermain, F., Denis Ducreux, François Bidault, et al.. (2005). Apport des nouvelles techniques d’imagerie à la planification radiothérapique des patients porteurs de glioblastome polymorphe. Bulletin du Cancer. 92(4). 333–342.9 indexed citations
5.
Faivre, Sandrine, Catherine Delbaldo, Karina Vera, et al.. (2005). Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. Journal of Clinical Oncology. 24(1). 25–35.934 indexed citations breakdown →
6.
Dhermain, F., R. de Crevoisier, Fabrice Parker, et al.. (2004). Récidives dans les tumeurs gliales : place de la radiothérapie. Bulletin du Cancer. 91(11). 883–889.14 indexed citations
Spano, Jean-Philippe, Pierre Busson, D Atlan, et al.. (2003). Nasopharyngeal carcinomas. European Journal of Cancer. 39(15). 2121–2135.155 indexed citations
9.
Hasbini, Ali, Éric Raymond, Esteban Cvitkovic, François Eschwège, & Jean‐Pierre Armand. (2000). Les carcinomes du nasopharynx. Bulletin du Cancer. 87(12). 21–26.2 indexed citations
Rivory, Laurent P., Marie‐Christine Haaz, Pierre Canal, et al.. (1997). Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.. PubMed. 3(8). 1261–6.125 indexed citations
12.
Armand, Jean‐Pierre, Vincent Dousset, Jean‐Michel Franconi, et al.. (1997). [Progressive multifocal leukoencephalopathy. Study of the demyelination by magnetization transfer].. PubMed. 78(2). 131–4.4 indexed citations
13.
Terret, C., C. Couteau, & Jean‐Pierre Armand. (1996). CPT-11: the European clinical development.. PubMed. 6(3). 152–7.2 indexed citations
Cambazard, F., Marek Haftek, C Hermier, et al.. (1988). [Harlequin fetus treated with etretin (RO 10-1670)].. PubMed. 115(11). 1128–30.3 indexed citations
20.
Armand, Jean‐Pierre, et al.. (1986). Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry.. PubMed. 46(4 Pt 2). 2105–12.38 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.